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Abstract
Purpose Metabolic tumour volume (MTV) is a promising prognostic indicator in diffuse large B cell lymphoma (DLBCL).
Optimal thresholds to divide patients into ‘low’ versus ‘high’ MTV groups depend on clinical characteristics and the measure-
ment method. The aim of this study was to compare in consecutive unselected patients with DLBCL, different software
algorithms and published methods of MTV measurement using FDG PET.
Method Pretreatment MTV was measured on 147 patients treated at Guy's and St Thomas’ Hospital. We compared 3 methods:
SUV ≥2.5, SUV ≥41% of maximum SUV and SUV ≥mean liver uptake (PERCIST) and compared 2 software programs for
measuring SUV ≥2.5; in-house ‘PETTRA’ software and Hermes commercial software.
Results There was strong correlation between MTVusing the 4 methods, although derived thresholds were very different for the
41% method. Optimal cut-offs for predicting PFS ranged from 166–400cm3. All methods predicted survival with similar
accuracy. 5y-PFS was 83–87% vs. 42–44% and 5y-OS was 85–89% vs. 55–58% for the low- and high-MTV groups, respec-
tively. Interobserver variation in 50 patients showed excellent agreement, though variation was lowest using the SUV ≥ 2.5
method. The 41% method was the most complex and took the longest time.
Conclusion All methods predicted PFS and OS with similar accuracy, but the derived cut-off separating good from poor
prognosis varied markedly depending on the method. The choice of the optimal method should rely primarily on prognostic
value, but for clinical use needs to take account of ease of use and reproducibility. In this study, all methods predicted prognosis,
but SUV ≥ 2.5 had the best inter-observer agreement and was easiest to apply.
Keywords Positron-emission tomography . Lymphoma . Diagnosis . Imaging
Introduction
Diffuse large B cell lymphoma (DLBCL) is the commonest
subtype of lymphoma, representing 30% of lymphoid
malignancies [1]. There has been a significant improvement
in cure rates in recent years, with the addition of rituximab to
cyclophosphamide, adriamycin, vincristine, and prednisone
(CHOP) chemotherapy. However, a significant proportion of
patients will progress or relapse after R-CHOP [2, 3] and long-
term cure rates are only about 60% [4]. Whilst first line treat-
ment has become more successful, salvage therapy after up-
front rituximab has become less effective [5, 6]. It is important
therefore to be able to reliably assess both pretreatment risk
and identify patients at high risk of progression or relapse
early to tailor treatment and test alternative approaches [7].
The International Prognostic Index (IPI) is currently used
for estimating pretreatment risk, despite the fact that IPI often
does not reliably predict individual patient outcome because
DLBCL tends to behave heterogeneously [8]. Other factors
that can predict prognosis, such as cell of origin or specific
translocations, e.g. double-hit lymphoma (myc and bcl-2
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translocations), have been identified but have not resulted in
therapeutic advances as yet [9, 10].
The response to treatment in DLBCL has great prognostic
value. Complete remission at the end of chemotherapy is as-
sociated with a high rate of progression-free survival (PFS)
[11], but this information is obtained too late for choosing
treatment. Positron emission tomography (PET) has been
found to be useful in early monitoring of treatment for aggres-
sive lymphomas [12]. In Hodgkin lymphoma, published
multicentre trials support the use of early ‘interim’ PET for
response-adapted treatment [13, 14]. However, in DLBCL,
whilst initial reports suggested interim PETcould reliably pre-
dict chemoresistance to CHOP [15, 16], later reports sug-
gested the introduction of rituximab might affect the interpre-
tation of Bpositive^ interim PET scans [1, 17, 18]. Currently,
the PFS of patients with a positive interim scan treated with R-
CHOP is around 50% at 2–5 years [17, 18]. Attempts to stan-
dardise PET reporting [11, 19] and improve the positive pre-
dictive value of interim PET using semi-quantitative ap-
proaches [20] have not been sufficiently improved to enable
interim PET to discriminate a group with poor prognosis in
whom a change of treatment would be warranted [21, 22].
Baseline imaging characteristics can also predict outcome
[23], including tumour burden [11]. The MInT study demon-
strated a linear relationship between maximum tumour dimen-
sion and prognosis in patients treated with R-CHOP [4]. More
recently metabolic tumour volume (MTV) has been identified
as a promising baseline prognostic factor [11, 24, 25] that is
superior to size-defined bulk [26, 27]. The high contrast
afforded by 18F fluorodeoxyglucose (FDG) PET imaging
may overcome some of the interobserver variability reported
when segmenting tumour regions using computed tomogra-
phy (CT) and it appears that PET is closer to the ‘ground truth’
when a tumour is delineated using PET compared to CT in
solid tumours [28, 29]. The use of PET automatic delineation
methods may also reduce interobserver variability [30].
Several methods have been proposed to measure MTVand
applied in selected patients with large cell lymphoma. This has
resulted in different cut-offs for MTV that separate good from
poor prognostic groups [24–26]. We recently reported our
experience measuring MTV using software developed in-
house. We combined baseline MTV with early response as-
sessment using Deauville criteria in consecutive unselected
patients with DLBCL treated with R-CHOP at a single insti-
tution [26] using quality assurance methods developed for
clinical trials [31]. Using this approach, a third of patients
were found to have high baseline MTV with incomplete early
metabolic response after 2 cycles of R-CHOP and 5y-PFS of
only 30% [26].
Validation of these data will require large patient numbers
and involvement of international groups. Standardisation of
the methodology for MTV is crucial for this endeavour, as
previously occurred with the assessment of PET response
using the Deauville criteria [11, 19]. Methods also need to
be available using commercial software and be robust and
easy to use in daily practice.
The aim of this study therefore was to:
1) Compare the reproducibility of measuring total MTV
using in-house software (as previously reported) [26]
and commercially developed software (Hermes Medical
Solutions, Sweden)
2) Compare various published ways to perform MTV
segmentation
3) Assess inter-observer variability in MTV measurement
and ease of use of different methods
4) Compare accuracy of the various MTV segmentation
methods to predict PFS and overall survival (OS) in
DLBCL [25, 26, 32, 33]
Patients and methods
Consecutive patients with DLBCL treated with R-CHOP at
Guy’s and St Thomas’ NHS Trust from 2005 to 2012 were
included [26]. Baseline PET/CTscans were acquired after a 6-
h fast and 90 min after administration of FDG produced in an
on-site cyclotron.
Images were acquired from the base of the skull to upper
thighs using DST or VCT scanners (General Electric,
Waukesha, WI, USA) for 5 minutes per bed position with
separate head and neck views, if required. CT parameters were
140 kV; 115mA; 0.5-s rotation time; 1.375 pitch. Images were
reconstructed using iterative reconstruction and displayed
using Hybrid Viewer (Hermes Medical Solutions, Sweden)
scaled to a fixed standardised uptake value (SUV) of 10 and
using a standard colour table.
MTV was measured on the baseline PET scan by one ob-
server (HI) using:
1. In-house software named ‘PET Therapy Response
Assessor’ (PETTRA) developed as part of a PhD project
to segment a tumour using counts with SUV ≥ 2.5
(PETTRA 2.5) as previously reported [26]
2. Commercial software ‘Hermes Hybrid 3D’ in develop-
ment by Hermes Medical to segment tumours using
SUV ≥2.5 (Hermes 2.5)
3. Volume with counts ≥41% of the maximum SUV within
individual tumour regions (Hermes 41%) by applying a
thresholding tool available within the Hermes Hybrid 3D
application [33]
4. Uptake higher than the mean SUV in a 3-cm3 cuboid
volume of interest (VOI) in the right lobe of the liver as
recommended by the authors of PERCIST (Hermes
PERCIST) [32]
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The first three methods involved automatic segmentation
of areas of tumour selected by the operator using a single-click
for each region.
In the PERCIST method, the operator placed a 3-cm3 VOI
in the right lobe of the liver. Awizard named ‘Tumour finder’
then automatically segmented all volumes within the image
with uptake ≥1.5 x mean SUV + 2 standard deviations (SD) in
the liver VOI. We also tested the exploratory threshold of 1 x
mean SUV + 2 SD suggested [32], but found it to be too sen-
sitive, selecting multiple areas that did not contain tumour
(data not shown). If the liver showed extensive lymphoma
involvement, a 1 × 1 × 2-cm VOI was placed in the descend-
ing thoracic aorta and used as the reference region instead
[32].
The operator then modified volumes as required—manual-
ly removing regions that contained only physiological FDG
uptake, e.g. brain or bladder, or by using editing tools to re-
move physiological uptake adjacent to the tumour that had
been automatically included in the volume, e.g. myocardial
or urinary tract and bowel uptake.
Individual tumour volumes, where more than one volume
was present, were summed to calculate the total MTV.
Observers were blinded to patient outcome.
Interobserver variation
To analyse interobserver variation, a secondmore experienced
observer (SFB) measured MTV independently from the first
observer (HI) using all 3 methods available in the Hermes
Hybrid 3D application in a subset of 50 patients. Five scans
were randomly selected from each decile of MTV (using
Hermes 2.5) to give a representative selection of high and
low values. Time to complete the measurement of MTV for
each method was also recorded.
Statistical analysis
Agreement was measured between the in-house and commer-
cial software (PETTRA 2.5 & Hermes 2.5), the three methods
available in the commercial software (Hermes 2.5, Hermes
41%, Hermes PERCIST) and the different observers (HI &
SFB).
The intraclass correlation coefficient (ICC) was used to
measure consistency between MTV values [34]. However,
since the Kolmogorov-Smirnov (KS) normality test revealed
a significant non-normal distribution (p < 0.001), MTV values
were transformed using the cube root (KS, p = 0.66) before
calculating the ICC. Kendall's tau correlation coefficient was
used to measure agreement in the ranked MTV values. Non-
parametric Bland-Altman plots were used to evaluate median
bias and limits of agreement (2.5% and 97.5% percentiles)
from the untransformed MTV values [35].
Survival analysis was performed for all four methods of
measuring MTV. PFS was defined as the time from diagnosis
to the point of progression or death from any cause. OS was
defined as the time from diagnosis to death from any cause.
Patients still alive were censored at the date of last contact.
Receiver operating characteristic (ROC) curves were used
to assess predictability of each MTV measure and identify
optimal cut-offs to predict PFS. Optimal cut-off points were
calculated as the minimum of the sum of squares of 1 – sen-
sitivity and 1 – specificity (the point nearest to the top left
corner of the ROC curve). Kaplan-Meier analysis was used
to estimate survival time statistics (median and 5-y PFS and 5-
y OS) for ‘low-’ and ‘high-MTV’ groups for each method.
The log rank test was used to test if groups had significantly
different survival curves. Univariate Cox regression was also
applied to each MTV measure to calculate hazard ratios be-
tween the groups. p < 0.05 was considered to be statistically
significant.
All statistics were calculated using R version 3.3.0 [36].
Results
Patient population
Results are available for 147 patients with a median follow up
of 3.8 years (range 1.3–7.9 years). Patient clinical character-
istics were as previously reported [26]. The 5-y PFS for the
whole group was 65.4% and 5-y OS was 73.7%.
The values obtained for MTV using the different methods
for the patient population are given in Table 1.
Agreement between in-house and commercial software using
the same segmentation threshold (SUV≥ 2.5)
There was strong agreement between the total MTVmeasured
in our previous publication using SUV ≥ 2.5 to segment tu-
mour with in-house software and the commercially available
software (Table 2). Bland-Altman analysis (Fig. 1) showed no
significant median bias nor trend in the difference in the un-
transformed MTV values, with a median difference of 0.03
and limits of agreement (LoA) for 2.5% and 97.5% percen-
tiles, respectively, of −72.5 and 240.7 cm3.
Agreement between different MTV segmentation thresholds
using commercial software
Agreement was strong and statistically significant between all
three methods (Table 2) and strongest between the 2.5 and
PERCIST methods. Rank correlation was also strongest be-
tween 2.5 and PERCIST methods with significant strong cor-
relations between 41% and the other two methods. There was
a marked difference, however, in the absolute values for MTV
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(Table 1) using the 41% method compared to the other
methods that used either SUV ≥ 2.5 or the mean liver SUV
(PERCIST). This is because the 41%method selected a small-
er proportion of tumour volume, especially where there was a
heterogeneous distribution. The mean and median values of
the 41% method were only 26% and 28% of the values using
the 2.5 method.
Nine patients categorised in the high MTV group using 2.5
were categorised as having low MTV using 41% and, con-
versely, 2 patients categorised as having highMTVusing 41%
were categorised as low MTV using 2.5. Five of these 11
patients progressed, 4 were in the high MTV group by the
2.5 method, and 1 in the high-MTV group using the 41%
method.
Although the SUV ≥ 2.5 and PERCIST methods showed a
strong correlation, the LoAs on the Bland-Altman plot
(Fig. 2a) were wide. The Bland-Altman analysis showed a
clear observable trend between mean value and difference,
between 41% and the other methods (Fig. 2b and c). A trend
between the SUV ≥ 2.5 and the PERCIST method was also
apparent (Fig. 2a). This was due to 11 patients with high
disease burden, where the MTV calculated using the
PERCIST method was higher than using SUV ≥ 2.5 because
the liver had lower uptake in these individuals (average liver
SUVmax was 1.6, average liver SUVmean was 1.0). A further
7 patients had liver involvement by lymphoma where the me-
diastinal blood pool, which has lower uptake than the liver,
was used instead as the reference region.
Inter-observer variation and ease of use
There was excellent agreement between the two observers for
measuring MTV with each of the methods using Hermes
software. The ICCs were 0.9996, 0.9831 and 0.9984, respec-
tively, for Hermes 2.5, Hermes 41% and Hermes PERCIST (p
< 0.001 for all methods).
Kendall’s tau coefficients were 0.9765, 0.9027 and 0.9639,
respectively (p < 0.001 for all methods).
Bland-Altman plots showed a median difference of 0.4
(LoA: −52.4 to 167.5), 0.0 (LoA: –48.8 to 144.6) and 1.1
(LoA: –126.9 to 112.3) for the 3 methods, respectively
(Fig. 3). No trends were observed.
The 41% method was the most time-consuming. The aver-
age time (and range) to measure total MTV using Hermes
software was 2.7 (0.2–10.7) minutes for the SUV ≥ 2.5 meth-
od, 6.2 (0.4–21.6) minutes for the ≥41%method and 3.2 (0.8–
8.1) minutes for the PERCIST method. The 41% method in-
volved a two-stage process to outline the tumour with a
constraining volume, find the maximum, then recontour using
41% of the maximum, rather than a single step as with the
SUV ≥ 2.5 approach. It also required editing of volumes in
patients where large areas of tumour involved several nodal
groups with heterogenous uptake. It is recommended that
where counts differ by more than 10%, regions should be
subdivided to avoid underestimation of tumour volume [33].
The PERCIST method was usually the quickest overall, as it
allowed automatic segmentation of regions using the wizard,
except in cases where there were separate head and neck
views where the observer had to delineate the regions sepa-
rately on this view.
Prediction of prognosis - ROC & survival analysis
The distribution and area under the ROC curves for all four
methods were similar, suggesting the methods to be close in
accuracy for the prediction of PFS (Fig. 4a) even though they
Table 2 In-house (PETTRA) and
commercial software (Hermes)
show strong correlation and close
limits of agreement (LoA) for
measuring MTV using the 2.5
method. The three different
methods using Hermes software
also show strong correlation and
LoAwith one another, with the
highest agreement observed be-
tween the 2.5 and PERCIST
methods
Intraclass coefficient
(ICC)
Kendall’s
tau
Median
difference
Lower
LoA
Upper
LoA
PETTRA 2.5 vs. Hermes
2.5
0.99 * 0.95 * 0.03 −72.5 240.7
Hermes 2.5 vs. Hermes
PERCIST
0.98 * 0.89 * 27.32 −2081.8 595.5
Hermes 2.5 vs. Hermes 41% 0.86 * 0.72 * 305.72 2.2 3770.2
Hermes PERCIST vs.
Hermes 41%
0.83 * 0.73 * 246.38 −2.5 6081.3
*p < 0.001
Table 1 Descriptive statistics for
MTV values Method Mean SD Min. Q1 = 25% Median Q2 = 75% Max.
PETTRA 2.5 990.14 1210.24 1.50 140.53 595.12 1411.75 7357.20
HERMES 2.5 989.14 1210.27 1.08 147.17 592.48 1387.28 7348.00
HERMES PERCIST 1057.21 1599.77 0 97.75 443.61 1344.06 8365.28
HERMES 41% 255.75 340.55 0 36.69 165.76 358.25 2443.29
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gave different cut-offs for ‘low’ and ‘high’MTV values. ROC
curves for OS (Fig. 4b) similarly yielded almost identical
curves with similar optimal thresholds for the methods, except
PERCIST. The optimal threshold for PERCIST for OS (670
cm3) was approximately twice as high as for PFS (327 cm3).
However, the method of choosing the optimal threshold bal-
ances both sensitivity and specificity. Considering this
grouped measure and imperfect ROC curves, the PERCIST
PFS threshold of 327 cm3 for OS was similarly optimal (spec-
ificity 53%, sensitivity 82%).
Kaplan–Meier analyses (Fig. 5a) showed that the patients
with low MTV have a significantly longer 5y-PFS compared
to the patients with high MTV, regardless of the method. The
5y-PFS was 87% versus 42% for the low- and high-MTV
Fig. 1 Bland-Altman plot of MTV2.5 measured using PETTRA (in-
house) software and Hermes (commercial) software. The horizontal axis
represents the mean of the two MTV methods and the vertical axis, the
difference between them. The solid line shows the median difference
(close to zero) and the dashed lines show the 95% limits of agreement
(LoA). The median is very close to zero, indicating no systematic differ-
ence between the methods, and the range of LoA is relatively small
compared to the scale of the MTV values, indicating a good numerical
agreement in the methods among the majority of patients
Fig. 2 Bland-Altman plots (see Fig. 1 caption for description) comparing
MTV measured by the different methods by a single observer. Compared
with Fig. 1, the LoAs on each plot cover a range closer to the range of
MTV values, indicating a poorer numerical match between each pair of
methods. Additionally, there is an observable trend: the difference in-
creases as the mean value increases, indicating a systematic difference
dependent on the MTV
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groups for the 2.5 methodwhich was identical using PETTRA
and Hermes software, 83% vs. 42% for the 41% method and
85% vs. 44% for the PERCIST method (Fig. 6).
Cox regression calculated the hazard ratios for PFS (high
MTV compared to low MTV) to be 5.9 [2.9–12.2 95% con-
fidence interval (CI)], 5.9 (2.9–12.2 CI), 4.8 (2.4–9.5 CI) and
4.2 (2.2–7.9 CI) for PETTRA 2.5, Hermes 2.5, Hermes
PERCIST and Hermes 41% methods, respectively (all
p < 0.001).
Patients in the low-MTV group also had significantly lon-
ger OS than patients in the high-MTV group using the optimal
PFS-derived thresholds with similar separation between high-
and low-MTV groups for all methods (Fig. 5b). The 5y-OS
was 89% vs. 55% for the 2.5 method, 85% vs. 56% (41%
method) and 86% vs. 58% (PERCIST method) (Fig. 5b).
The hazard ratios for OS were 5.5 (2.4–12.5), 5.5 (2.4–
12.5), 3.7 (1.8–7.8) and 3.5 (1.8–7.0) for PETTRA 2.5,
Hermes 2.5, Hermes PERCIST and Hermes 41% methods,
respectively (all p < 0.001).
Discussion
Baseline MTV, using FDG-PET, is a promising prognostic
indicator in patients with DLBCL, which is better than using
size-defined bulk [25, 26]. Tumour lesion glycolysis, which is
the MTV multiplied by the mean SUV in the volume, is also
prognostic [37], but appears no better than MTV in DLBCL
[26, 27]. Cut-offs ranging from 220 to 600 cm3 have been
reported to separate patients into groups with low and high
baselineMTVs (Table 3) which are predictive of PFS and OS.
Cut-offs have been derived using ROC curve analyses
[24–27] that depend on the distribution of values in the
dataset, which are influenced by patient characteristics
(Table 3), with populations with worse clinical characteristics
tending to have a higher optimal cut-off for MTV, but also
crucially, as demonstrated in our study, on the method used
to outline the tumour volume. The influence of the method of
measurement on the optimal cut-off has been previously re-
ported in 59 patients with Hodgkin lymphoma [39] and 106
patients with T cell lymphoma [40]. For clinical use, a con-
sensus will be required on a suitable method and an optimal
cut-off to define the MTV for specific lymphoma subtypes
and treatment regimens, which will require validation in
multicentre prospective trials.
Algorithms have already been developed for segmentation
of volumes for radiotherapy planning purposes in solid tu-
mours [41, 42]. Boundaries can be chosen using an absolute
SUV value or a percentage of the maximum SUV.
Alternatively, more complex methods may be adopted, such
as contrast-orientated, possibility theory and adaptive
thresholding. No single method is likely to perform optimally
in every patient, and consensus methods, such as the majority
vote, have been reported to improve accuracy compared with
the ‘ground truth’ of manual delineation by experts or surgical
specimens [43]. In a recent publication, consensus methods
performed better than the worse performing of three
established automatic segmentation methods and were close
to the best-performing method in all patients [43]. Five seg-
mentations were implemented in a single software platform
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Fig. 3 Bland-Altman plots (see Fig. 1 caption for description) comparing
MTV measured by the different methods by two different observers. The
median difference (solid lines) is close to zero for all three methods,
indicating no systematic bias. The LoAs (dashed lines) are close, indicat-
ing good agreement
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for evaluating patients scanned on four different cameras with
lung and breast tumours and which also included eight pa-
tients with lymphoma.
So far in DLBCL, three methods have been proposed in the
literature for measuring MTV [26, 32, 33]. Importantly none
of these methods are vendor-specific and we have demonstrat-
ed that measurement using the 2.5 method is robust using in-
house software and commercial software. Efforts are being
made to develop automated freeware incorporating all the
published methods [39], but whether this will be acceptable
for making patient management decisions using MTV as a
prognostic tool remains to be seen.
We tested these methods in a population of consecutive
patients with de novo DLBCL treated with standard R-
CHOP at a single institution, likely to be representative of
the general patient population. We did not measure CT-
based tumour burden as the CT component of the PET-CT
scans were performed as low-dose non-contrast scans, in
keeping with our usual clinical practice. The first method
measured any activity that may be significant with a SUV
greater than 2.5 [26]. The second method was derived from
phantom experiments to give the best estimate of anatomical
volume [33]. The third method also measured any significant
activity, but using liver uptake as the threshold [32], which
may be less influenced by factors that cause inaccuracy in
SUV measurement, but which may be more dependent on
patient preparation and metabolic status, with reduction in
normal liver uptake observed when there is very high tumour
burden at baseline [38].
The in-house and commercial methods for measuring
MTV using the 2.5 method gave almost identical results.
The PERCIST method was very close to the 2.5 method, but
probably overestimated MTV in approximately 12% of pa-
tients who had low FDG uptake in the liver or liver involve-
ment by lymphoma. The 41% method was very different in
absolute MTV values compared to the other methods and was
more susceptible to measurement variability when there was
tumour heterogeneity.
Accordingly, we found the optimal cut-off for MTV to
predict PFS ranged from 166 to 400 cm3. Although all three
methods could predict PFS with similar accuracy in the over-
all study population, we found for some individual patients
with very intense masses, the 41% method appeared to under-
estimate tumour volume compared with the other methods.
The 2.5 method gave an optimal cut-off in our study popula-
tion (400 cm3) which was in the middle of the cut-offs previ-
ously reported by Song and colleagues using this method in
two publications. The first measured MTV in good-prognosis
patients with no extranodal involvement (derived cut-off
220 cm3) [25] and the second in poor-prognosis patients, all
of whom had bone marrow involvement (derived cut-off
600 cm3) [44]. The 41% method gave an optimal cut-off in
our population which was much lower than the 550 cm3 [24]
and 300 cm3 [40], respectively, reported by Meignan and col-
leagues in two publications. There were twice as many pa-
tients over the age of 60 in the study with the lower cut-off,
which is surprising as increased age is generally associated
with worse prognosis. Therefore, the cut-off might have been
expected to be higher in an older population (Table 3). Other
clinical characteristics were similar in these two studies. The
variability in the cut-offs reported for the 41% method raise
concerns that the optimal cut-off may be more dependent on
how regions are selected by different groups, when there is
considerable tumour heterogeneity.
There was high interobserver agreement for measuring
MTV with all methods. The 41% method was the most com-
plex to use in our experience, reflected in the time taken to
measureMTVin a subset of 50 patients. The PERCISTmethod
was usually the quickest, because it allowed automatic segmen-
tation of all regions on the scan, using the ‘tumour finder’
wizard (©Hermes Medical Solutions). This was despite need-
ing to edit out areas that had uptake above the liver, accounted
for by areas with high physiological uptake such as the brain
and bladder. Inflammatory uptake might also require editing,
but we did not observe this in the patients in our study (Fig. 6).
The study confirmed that the prognostic role of baseline
MTV [26] using software developed in-house could be
reproduced accurately using commercially developed soft-
ware. We previously found that baseline MTV was a good
prognostic indicator, better than size-defined bulk [26].
Using all three methods, 5y-PFS in the current study was
similar to the values reported in our earlier manuscript of
43% for patients with high MTV compared to 85% for pa-
tients with low MTV [26] and compares favourably with pre-
vious publications [24, 40]. The sensitivity and specificity of
the three methods is shown in Fig. 4.
We combined baseline MTV with early response assess-
ment at two cycles in an attempt to improve prognostic value
in our previous work [26]. High MTVand failure to achieve a
complete metabolic response (Deauville score 4,5) at 2 cycles
was found in 31% of patients who experienced 58% of study
events with 5y-PFS of only 30%. CombiningMTVwith base-
line factors rather than early response might be a more attrac-
tive option. Recently, El-Galaly and colleagues [23] reported
that combining baseline PET findings with the new National
Comprehensive Cancer Network (NCCN) IPI, which splits
patients according to age groups >40, >60 and >75 years
and by LDH levels 1–3 or >3 times the upper limit of normal,
was better at predicting prognosis than PET combined with
the IPI or revised IPI. Furthermore, the number of involved
Fig. 4 ROC curves for PETTRA 2.5, Hermes 2.5, Hermes 41% and
Hermes PERCIST for a) PFS and b) OS. The tables show the area
under the curve (AUC) with 95% confidence intervals (95% CI), opti-
mum threshold value for each MTV (Thr), with associated sensitivity
(sens) and specificity (spec)
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extranodal sites and the presence of bone/bone marrow, pleura
and female genital organ involvement was associated with
inferior prognosis. Combining NCCN-IPI and MTVand pos-
sibly other baseline imaging features as suggested by el-
Galaly and colleagues [23] might be even more informative.
The cell of origin is also known to influence prognosis,
with the activated B cell (ABC) subtype conferring a worse
prognosis than the germinal centre B cell (GCB) subtype [9].
Genetic rearrangements including overexpression of BCL2
and MYC which regulate apoptosis and proliferation area
are also associated with inferior prognosis [10, 45].
Cottereau et al. reported on 81 patients [40] mostly with ad-
vanced stage DLBCL, combining molecular profiling data
with MTV. High MTV using a cut-off of 300 cm3 (by 41%
method) was associated with identical 5y-PFS of 43% in our
study. The subset of 16 patients with high MTVand the ABC
subtype had 5y-PFS of 30% and OS of 23%. Patients with
overexpression of BCL2 and/or MYC had inferior prognosis
irrespective ofMTV.MTV, however, separated the 55 remain-
ing patients into good- and intermediate-prognosis groups.
This suggests a potential for the strategy of combining
Fig. 6 An example of a case outlined using the 2.5 method (blue), the
41% method (red) and the PERCIST method (purple) with representative
coronal, sagittal, axial and 3D images. The top panel shows the initial
‘automatic’ volumes. All methods result in similar volumes for disease
below the diaphragm (black arrow, sagittal view). However, for disease
above the diaphragm, the MTV is grossly underestimated using the 41%
method and separate bounding boxes of differing sizes have to be drawn
(green boxes in the bottom panel) to delineate 2 additional volumes,
increasing the time and complexity of MTV selection. The PERCIST
method detects physiological uptake in the brain and urinary tract (purple
arrows) which must be edited out by the observer
Fig. 5 Kaplan–Meier survival curves for PETTRA 2.5, Hermes 2.5,
Hermes 41% and Hermes PERCIST for a) progression-free survival
(PFS) and b) overall survival (OS). Both plots use PFS-derived optimal
thresholds to define high and low MTV. Solid line = low-MTV group ,
dotted lines = high-MTV group (defined by optimal thresholds). **
p < 0.001. The table shows log-rank scores from comparison of non-
progressor (N) & progessor (P) for each MTV method, with number of
events, 5-year PFS ([5y-PFS) and median survival in days (Med-Surv).
Log-rank scores revealed significant differences in PFS between
progressors & non-progressors with all methods. No non-progressor
groups reached below 50% PFS (i.e. no median survival is available)
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imaging and other biomarkers for pretreatment risk referred to
as ‘Radio(gen)omics’. Evaluation will involve pooling of data
to derive and validate risk estimates with international
collaboration.
In summary, all the published methods for measuring
MTV in DLBCL were prognostic in our study for PFS and
OS. The optimal cut-off using the 2.5 method in this unse-
lected patient population was in line with cut-offs published
by another group using this method in two populations with
good and poor prognosis, respectively. A limitation was that
scans were acquired at 90 min, longer than currently recom-
mended by EANM procedural guidelines [46]; nonetheless,
in our hands, the 2.5 method had the advantage of being easy
to use and reproducible across different software platforms
and between observers. In our opinion, contouring methods
based on percentages of the maximum uptake in the volume
may be easier to apply in solid tumours [42, 46] than in
DLBCL, where patients often present with multiple regions
with heterogeneous uptake. Developments in software may
overcome some of the difficulties with measurement that we
encountered.
The methodology is evolving and will require prospective
validation in sufficiently large patient cohorts combined with
other prognostic factors, to determine whether robust pre-
treatment risk estimates can be identified to select patients in
whom to test alternative treatments including novel agents.
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